1. Screening for tuberculosis in neuro-ophthalmology
- Author
-
Leanne M. Little, Rod Foroozan, Andrew G. Lee, and Edward A. Graviss
- Subjects
medicine.medical_specialty ,Tuberculosis ,biology ,business.industry ,Biomedical Engineering ,Effective management ,Disease ,bacterial infections and mycoses ,medicine.disease ,biology.organism_classification ,Tb exposure ,QuantiFERON ,Surgery ,Neuro-ophthalmology ,Mycobacterium tuberculosis ,03 medical and health sciences ,Ophthalmology ,0302 clinical medicine ,030228 respiratory system ,030221 ophthalmology & optometry ,medicine ,Intensive care medicine ,business ,T-SPOT.TB ,Optometry - Abstract
Introduction: Timely detection of Mycobacterium tuberculosis (Mtb) remain critical in the effective management of patients with suspected tuberculosis (TB) disease. While recommendations for determination of latent TB or TB exposure in industrialized countries support the use of interferon-gamma release assays (IGRA), including the QuantiFERON Gold In-Tube (QFT-GIT) and T-SPOT.TB tests, disagreement exists within neuro-ophthalmologic practice on screening protocols for TB which affects ocular function.Areas covered: The authors have reviewed the current literature discussing the manifestation of tuberculosis in neuro-ophthalmic disease. Our literature search expands on current recommendations for TB screening in neuro-ophthalmology, including a comparison of the currently available tests for screening: the TST, QFT-GIT, and T-SPOT.TB tests. We review the literature on regional TB prevalence as it applies to clinical decision making for screening, as well as medical and social factors which may cre...
- Published
- 2016
- Full Text
- View/download PDF